Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder (March 12, 2012) Reviva interview with MergerMarket - A Financial Times Publication (February 6, 2012) Reviva News Release (September 2011) IMS R&D Focus Drug News (November 2010)           5941 Optical Court,       San Jose, CA 95138. Map this location Telephone:+1 408 960 2209 FAX:+1 408 960 2206 Web : www.revivapharma.com   Reviva Pharmaceuticals Inc. © 2009 Privacy Policy Home Corporate R & DNewsCareersContacts